Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

  • Webinar Wednesdays is planned to be held on the last Wednesday of each month - starting on Wednesday, April 24th (at 1PM Eastern) with the first webinar on the increasing prevalence of non-small cell lung cancer in never smokers and how drug candidate LP-300 and the Harmonic Clinical Trial is looking to change these outcomes.
  • The second Webinar Wednesdays will focus on drug development needs in an area of critical patient need, pancreatic cancer, and how drug candidate LP-184 can address tumors with certain genomic and mutational profiles – this webinar is planned for Wednesday, May 29th (at 1pm Eastern).
  • The webinars will feature world-class collaborators and researchers, such as Dr. Joseph Treat and Dr. Igor Astsaturov of Fox Chase Cancer Center and Dr. Marc Chamberlain of Starlight Therapeutics.

DALLAS--()--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that – the company has launched Webinar Wednesdays, a webinar series that focuses on areas of high oncology drug development interest with leading physicians, scientists and Lantern collaborators in drug development and artificial intelligence. The series begins today, Wednesday, April 24, 2024, and is planned to be held on the last Wednesday of each month.

Each webinar will feature a presentation from a Lantern collaborator, advisor, or researchers followed by a live Q&A. These sessions provide a deep dive into the company’s research, collaborations, clinical trials and expected goals for the drug or AI development initiatives. The series kicks off today, Wednesday April 24, focusing on LP-300, a novel therapeutic for the treatment of non-small cell lung cancer in never-smokers presented by Dr. Joseph Treat. Next month Dr. Igor Astsaturov will share his experience, and approach for the treatment of pancreatic cancer and other solid tumors and how synthetically lethal drug candidate, LP-184 fits into an increasingly biomarker driven paradigm for cancer treatments.

Future topics will include Starlight Therapeutics, a subsidiary of Lantern Pharma that focuses on central nervous system and brain cancers, and updates on RADAR®, Lantern’s proprietary AI and ML platform for oncology drug development and computational onco-biology at-scale.

————

April’s Webinar Wednesday

April 24, 2024 – 1:00pm Eastern
“LP-300 in Never-Smokers with Non-small Cell Lung Cancer”
Register here: https://bit.ly/3vO117s

Join Joseph Treat, MD and Reggie Ewesuedo, MD to explore lung cancer in never-smokers, defining its uniqueness, challenges that patients are facing, and the successes and future of the Harmonic™ Phase 2 clinical trial for LP-300 in never-smokers with non-small cell lung cancer.

Presentation: Joseph Treat, MD

Joseph Treat, MD, is principal investigator of the Harmonic™ study in the United States and a leading expert in lung malignancies, including non-small cell lung cancer in never-smokers. Dr. Treat is a Professor in the Department of Hematology and Oncology, Vice Chair of Education, and Medical Director of Ambulatory Care at Fox Chase Cancer Center.

Q&A: Reggie Ewesuedo, MD

Reggie Ewesuedo, MD, is Vice President of Clinical Development at Lantern Pharma. Dr. Ewesuedo has more than 20 years of expertise in drug development research activities and has served in clinical research lead capacities at The Ohio State University, AstraZeneca, Genzyme, Sanofi, Pfizer, Tesaro/GlaxoSmithKline, and Kymera.

May’s Webinar Wednesday

May 29, 2024 – 1:00pm Eastern
“LP-184 in Pancreatic Cancer and Other Solid Tumors”
Register here: https://bit.ly/3U9NizL

Join Igor Astsaturov, MD and Kishor Bhatia, PhD to explore the science of pancreatic cancer and other solid tumors, challenges around diagnosis and treatments of the disease, and LP-184 as a promising agent for these tumors with ongoing Phase 1 trial and multiple preclinical validations.

Presentation: Igor Astsaturov, MD

Igor Astsaturov, MD is a leading expert in pancreatic cancer collaborating with Lantern Pharma on the LP-184 clinical trial. Dr. Astsaturov is an Associate Professor in the Department of Hematology/Oncology, Co-Director of the Marvin & Concetta Greenburg Pancreatic Cancer Institute, and Inaugural Holder of the Paul F. Engstrom Professorship in Oncology.

Q&A: Kishor Bhatia, PhD

Kishor Bhatia, PhD, is Chief Scientific Officer at Lantern Pharma. Kishor brings more than 40 years of experience in cancer research, which has included roles such as Director of the Children’s Cancer Center Riyadh and Director of the Office of AIDS Malignancy Program at the National Cancer Institute (NCI).

_________________

About Lantern Pharma:

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program.

Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.

Please find more information at:

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," “model,” "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research of our collaborators may not be successful, (ii) the risk that promising observations in preclinical studies do not ensure that later studies and development will be successful, (iii) the risk that we may not be successful in licensing potential ADC candidates or in completing potential partnerships and collaborations, (iv) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (v) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vi) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 18, 2024. You may access our Annual Report on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this presentation represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

Lantern Pharma Disclosure Channels to Disseminate Information:

Lantern Pharma’s investors and others should note that we announce material information to the public about our company and its technologies, clinical developments, licensing matters and other matters through a variety of means, including Lantern Pharma’s website, press releases, SEC filings, digital newsletters, and social media, in order to achieve broad, non-exclusionary distribution of information to the public. We encourage our investors and others to review the information we make public in the locations above as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Contacts

Investor Relations – IR@lanternpharma.com

Contacts

Investor Relations – IR@lanternpharma.com